The global viral vector development market is on the cusp of a transformative growth phase, driven by significant advancements in gene therapy and vaccine innovation. According to a recent study conducted by Future Market Insights, the market is expected to reach an impressive USD 4.1 billion by 2033, reflecting a robust Compound Annual Growth Rate (CAGR) of 18.7%.
By the end of 2023, the market is anticipated to achieve a substantial milestone of USD 730.7 million, underscoring a rising interest and adoption of viral vectors for therapeutic applications. This surge is largely attributed to the increasing demand for innovative treatments and advanced biopharmaceutical technologies.
Adeno-associated viral vectors (AAV) have emerged as key players in this growth trajectory, projected to capture a significant market share of approximately 37.0% by the close of 2023. Their unparalleled versatility in gene therapy and vaccine development positions them as indispensable tools within the biopharmaceutical landscape.
“The exponential growth of the viral vector development market underscores the escalating demand for cutting-edge treatments and vaccines,” remarked a representative from Future Market Insights. “AAVs, in particular, are transforming the landscape by enabling precise delivery and enhancing therapeutic efficacy.”
The study further highlights the vital role of technological advancements and strategic collaborations in driving market expansion. As investments and research initiatives continue to rise, stakeholders in the viral vector development sector are well-positioned to capitalize on emerging opportunities, paving the way for unprecedented growth.
Key Takeaways:
- Gene therapy is vital to repair suppressed and malfunctioning genes in human cells or tissues and helps in returning the abnormality to a normal level. Viral vector technology is commonly utilized to cultivate the gene. Furthermore, this business has grown for many private players. For the most part, two different types of techniques are used to use viral vectors in the gene therapy-induced healing process.
- When it comes to 2D planer technologies, scaling out of adherent cell systems is one of the common strategies that is applied until the point of market analysis. The production of suspension AAV by diverse segments will, therefore, rely increasingly on 3D suspension cell cultures or bioreactors in the upcoming period.
- The propelling synthesis of viral vectors utilizing cell culture technology has been modified successfully in order to satisfy the demands of both early and advanced clinical trial Scale-up, however, may still be constrained depending on the vector type and the cell culture production platforms chosen.
- At present, visible progress is being made within the generation of cell lines that are able to create inducible or constitutively expressed lentiviral vectors that grow in suspension. Over the past few years, the first batch of lentiviral vectors generated by reliable producer cell lines was utilized in a clinical trial setting.
- With extensive safety and efficiency, the data gathered from numerous clinical trials show that gene therapy is making great progress. These factors are set to promote the expansion of the global market, over the forecast period.
High Demand for Market Insights: Discover Comprehensive Trends in Our Full Report!
Competitive Landscape:
Over recent years, the market for the production of plasmid DNA and viral vector CDMO has become extremely competitive. This has resulted in the introduction of numerous companies in these industries. The main tactic used by the leading firms to stay ahead of their rivals is the expansion of production facilities. A cost-effective strategy for the rapid expansion and capacity building for viral vector process development for the manufacturers is the acquisition of small regional companies.
Key Companies Covered:
- Thermo Fisher Scientific Inc
- Charles River (Cobra Biologics)
- NOVASEP
- uniQure N.V
- Waisman Biomanufacturing
- Creative Biogene
- GenScript Biotech Corporation
- Novartis AG
- Merck KGaA
- Takara Bio, Inc.
- FUJIFILM Diosynth Biotechnologies
- LONZA
- Danaher Corp. (Aldevron)
- Sirion Biotech GmbH
- AGC Biologics
More Insights into the Viral Vector Development Market:
The North American region is anticipated to dominate the global viral vector development market over the assessment period as it accounted for a total of 33.1% in 2022. The USA is expected to continue to grow its dominance in the global market within the next decade.
Key Market Segments Covered in Viral Vector Development Industry Research
Virus:
- Lentiviral Vectors
- Adenoviral Vectors
- Adeno-Associated Viral Vectors
- Retrovirus
Expression System:
- Transient
- Stable
Application:
- Gene Therapy
- Vaccines
- Cancer Therapy
- Others
End User:
- Biotechnology Companies
- Pharmaceutical Companies
- Contract Research Organization (CRO)
- Academic and Research Institutes
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- The Middle East and Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
